From the Department of Biochemistry, Bioproducts Research Center and Yonsei Proteome Research Center, Yonsei University, 134 Shinchon-dong, Sudaemoon-ku, Seoul 120-749, Korea
Received for publication, February 22, 2000, and in revised form, March 12, 2001
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The 7-dehydrocholesterol reductase (Dhcr7) is the
terminal enzyme in the pathway of cholesterol biosynthesis. We have
previously reported that sterol depletion in vivo caused a
significant induction of both liver mRNA and enzyme activity of
Dhcr7 (Bae, S.-H., Lee, J. N., Fitzky, B. U., Seong, J., and
Paik, Y.-K. (1999) J. Biol. Chem. 274, 14624-14631).
In this paper, we also observed liver cell-specific sterol-mediated
Dhcr7 gene induction in vitro by sterol depletion in rat
hepatoma cells, suggesting the presence of sterol-mediated regulatory
elements in the Dhcr7 gene. To understand the mechanisms responsible
for regulating Dhcr7 expression, we have isolated the 5'-flanking
region of the gene encoding rat Dhcr7 and have characterized the
potential regulatory elements of the gene that are responsible for
sterol-mediated regulation. The Dhcr7 promoter contains binding sites
for Sp1 (at The 7-dehydrocholesterol reductase
(Dhcr7,1 EC
1.3.1.21) catalyzes the reduction of the
Recently, cDNAs encoding Dhcr7 from mouse (22), rat (4), human (7),
and Arabidopsis thaliana (23) have been isolated. Dhcr7
mRNA was expressed mainly in liver and its regulation appeared to
be controlled by tissue sterol contents as well as some cholesterogenic inhibitors (2, 4). However, molecular cloning and the nature of
sterol-mediated transcriptional control of the Dhcr7 gene in any
species have not been reported previously. Furthermore, the relative
importance of multiple motifs at the 5'-flanking region in
transcriptional regulation of the Dhcr7 gene is also not known. In
order to characterize the 5'-flanking region and the response of
multiple regulatory elements to sterols, we isolated the 5'-flanking region of the rat Dhcr7 gene and the complete genomic sequence (GenBankTM accession number
AF279892).2 In this paper, we
describe the promoter activity and the sterol-mediated regulation of
this gene by various mutation analyses, with emphasis on the proximal
promoter ( Materials--
A rat Promoter FinderTM DNA Walking
Kit was purchased from CLONTECH (Palo Alto, CA).
The following materials were purchased from manufacturers, as
indicated. Hyper x-ray film, [ RNA Preparation and Northern Blot Analysis--
RNA was isolated
by phenol-chloroform extraction using TRI reagent Kit (Molecular
Research Center Inc.). Total RNA (20 µg) was electrophoresed in a 1%
formaldehyde-agarose gel and vacuum-transferred to Hybond
N+ membrane (Amersham Pharmacia Biotech) with 20 × SSC (150 mM NaCl, 15 mM sodium citrate, pH
7.0). After prehybridization of the membranes at 42 °C for 5 h
in 5 × SSC, 10 × Denhardt's solution, 100 µg/ml denatured herring sperm DNA, the membranes were hybridized to 32P-labeled rat Dhcr7 cDNA probe for 18 h. Then
the membranes were washed with 0.1% SSC, 0.1% SDS at 65 °C.
Hybridization signals were visualized by autoradiography using Hyper
x-ray film with an intensifying screen at Cloning of the 5'-Flanking Region of the Rat Dhcr7
Gene--
At the initial stage of this work, rat Dhcr7 promoter was
amplified from DNA provided in the rat Promoter FinderTM
DNA walking kit (CLONTECH) according to the
manufacturer's instructions. The primer r7R-9 (+49 ~ +28)
5'-GCGTGCGGGATCCGGGCGGTTG-3', corresponding to the cDNA for rat
Dhcr7, and anchor primer AP1 of the promoter finder kit were used in
the primary PCR. The primary PCR products were diluted and used for the
secondary PCR with nested primer r7R-48 (+31 ~ +7)
5'-GTTGATTCCAAGCTCCAGCAGCGCC-3' in the 5' region of Dhcr7 and
anchor primer AP2. Secondary PCR products were cloned into pT7Blue(R)-T
vector and sequenced with an ABI automated DNA sequencing system. The
cloned Dhcr7 promoter region was also confirmed by data obtained from
genomic clone sequencing.
Construction of Dhcr7-Luciferase Recombinant Plasmids--
To
analyze Dhcr7 promoter, the 5'-flanking region of the gene was ligated
into the luciferase reporter vector as follows. The parent plasmid,
p7R1084, was constructed by Klenow enzyme treatment of a DNA fragment
(NdeI/EcoRI) spanning Mutation Analysis of the Promoter Region--
The various mutant
constructs were generated by PCR using the wild type Dhcr7 promoter DNA
as a template with Pfu polymerase and mutagenic
oligonucleotides designed to introduce each specific multibase point
mutation. The mutated Dhcr7 promoter constructs were designated as M1
to M14. The sequences of the oligonucleotides used for the mutation of
the different parts of the Dhcr7 promoter are shown below, with the
mutated sequences in bold: SRE/m ( Cell Culture and Transfection of Cells--
HepG2, CHO-K1, and
H4IIE cells were grown in RPMI medium 1640 (Life Technologies, Inc.)
supplemented with 5% (v/v) FBS, 1 mM glutamine, and
10 µg/ml gentamycin in a 5% CO2 incubator at 37 °C.
Cells plated onto 6-well plates were grown to 50-70% confluence before transfection. Two µg of test constructs were co-transfected into HepG2 cells with 0.2 µg of Renilla luciferase control
vector, pRL-SV40 (Promega). Each plasmid containing Dhcr7
promoter-luciferase fusion gene and 2.0 µl of Lipofectin
reagent (Life Technologies) was diluted into 80 µl of Opti-MEM I
(Life Technologies). Plasmid DNA and Lipofectin reagent were then
combined and added to each plate according to the Lipofectin
manufacturer recommendations. The cells were transfected on serum-free
media for 18 h and then were switched to a medium with 5% LPDS
plus 10 µM Lovastatin (designated as sterol starvation
condition) or 1.5 µg/ml 25-hydroxycholesterol (designated as sterol
rich condition). After incubation for 48 h, with the appropriate
medium, cells were harvested, and extracts were assayed for luciferase
activity (see below for details).
Preparation of Cell Extracts and Luciferase Enzyme
Assays--
Following transfection and drug treatment, the cells were
washed with phosphate-buffered saline and lysed in 0.5 ml of 1 × passive lysis buffer (Promega). Cell extracts were assayed for Firefly and Renilla luciferase activities using
the Dual-luciferase Reporter Assay SystemTM according to
the manufacturer's recommendations (Promega). Amounts of lysates
employed for the Firefly luciferase activity assays of test
constructs were normalized to the Renilla luciferase activities.
DNase I Footprinting Assays--
32P-Labeled DNA
probes ( Electrophoretic Mobility Shift Assays (EMSA)--
Recombinant
ADD1 (amino acid residues 284 to 403 including the bHLH-LZ domain) was
overexpressed in Escherichia coli and purified from the
culture extracts as described previously (24). Rat hepatoma H4IIE cell
nuclear extracts were prepared according to the method of Dignam
et al. (25). Nuclear extracts were quantified by the
Bradford assay (Bio-Rad) and stored at Induction of Dhcr7 Gene by Sterol Starvation--
We have
previously reported (4) that when rats were maintained on a sterol
starvation condition by feeding CL-diet (5% (w/w) cholestyramine plus
0.1% (w/w) Lovastatin in chow) for 14 days, both hepatic mRNA
expression and the specific enzyme activity of Dhcr7 were increased
in vivo about 3- and 5-fold, respectively. To examine if
this type of sterol-mediated Dhcr7 induction can also be seen in
cultured cells in vitro, Northern blot analysis was
performed using Dhcr7 mRNA obtained from H4IIE cells and CHO-K1 cells that had been maintained in either FBS or LPDS medium. As shown
in Fig. 1A, mRNA from the
Dhcr7 gene was specifically induced more than 3-fold in
H4IIE cells (hepatic cells). However, this induction by sterol
depletion was seen only slightly in CHO-K1 cells (non-hepatic cells).
Dhcr7 mRNA was highly inducible in a dose-dependent
manner when cells were grown under sterol starvation conditions, where
cells were treated with the two cholesterogenic enzyme inhibitors,
AY-9944 (Dhcr7 inhibitor) and Lovastatin (HMG-CoA reductase inhibitor)
(Fig. 1, B and C). In contrast to this
observation, the Dhcr7 gene was suppressed by treatment of cells with
25-hydroxycholesterol (Fig. 1D). These results predicted
sterol-mediated regulatory sequences in the Dhcr7 gene. To test this
possibility, we isolated and analyzed the 5'-flanking region of this
gene in detail.
Mapping of Multiple Sterol-responsive Motifs--
A 1.1-kilobase
upstream fragment of the putative transcription initiation site from
the rat genomic clone was isolated, sequenced, and analyzed to identify
several cis-acting regulatory elements. The transcription
initiation site was previously determined.2 The nucleotide
sequence (1,053 bp), including exon 1, its 5'-flanking region, and part
of intron 1, is shown (Fig. 2). The
proximal region ( Deletion Analysis of Dhcr7-Luciferase Recombinant DNA for
Sterol-response Regulation--
To identify the transcriptional
regulatory regions in rat Dhcr7 gene and to determine whether this
region is regulated by exogenous sterols, a nested series of fragments
containing various lengths of the 5'-flanking region, together with a
part of the first exon (+31 out of 52 bp) were generated by either PCR
or restriction endonuclease digestion. The parental plasmid used for
this study was designated as p7R1084, spanning nucleotides
To examine which oxysterol may be most effective in suppression of the
Dhcr7 promoter, luciferase activities were measured for p7R318
( Interaction of Recombinant ADD1 Transcription Factor with Promoter
Sequence of Dhcr7--
To characterize transcription factors binding
to the Dhcr7 promoter, ADD1, a rat homolog of human SREBP-1, was
overexpressed. DNase I footprinting and EMSA were performed using the
DNA fragment covering Mutational Analysis of Sterol-mediated Regulatory Sequences within
Dhcr7 Promoter--
Fig. 3 demonstrates that the Activation of Dhcr7 Promoter by SREBP-1--
Activation of Dhcr7
gene transcription by sterol starvation required GC3 and CCAAT1, in
addition to the SRE1/E box (Fig. 8). Thus, co-regulatory transcription
factors, such as Sp1 and NF-Y, may function in concert with SREBP-1
(ADD1) to mediate the sterol-regulatory response of the Dhcr7 gene (32,
37, 38). To test this, Dhcr7 transcription was measured by SREBP-1
co-transfection (24). As shown in Fig.
9A, the activity of
Dhcr7-directed luciferase activity increased in a
dose-dependent manner up to 50 ng when cells were
co-transfected with pSREBP1. The activity of the Dhcr7 promoter by
pSREBP1 was abolished when the sequence containing GC3 and CCAAT1 was
deleted (Fig. 9B), suggesting that either Sp1 binding to GC3
or NF-Y binding to CCAAT1 is necessary for SREBP-1-mediated activation
of the promoter. To further analyze the specificity and potential
mechanism for this activation, we employed mutational analysis to find
which regulatory element (i.e. GC3 or CCAAT1) is more
critical for activation by SREBP-1 overexpression. These various point
mutants in cis-acting elements of the Dhcr7 promoter were
compared with wild type promoter for activation where the SREBP-1 was
supplied exogenously from an expression plasmid. Interestingly, the
mutation of CCAAT1 (M5, 6) and SRE1/E box (M8; Refs. 13 and 14)
resulted in significant reduction (i.e. 35 and 58%) of
SREBP activated Dhcr7 promoter activity as compared with the wild type
(Fig. 10). However, mutation of GC3
(M2, 3) resulted in a less significant reduction of the activation rate
when pSREBP1 plasmid was added. This result is also consistent with the
data shown in Fig. 9B. A mutant construct of p7R148, in
which GC3 was deleted, sustained 5.7-fold activation by co-transfection
with pSREBP1. These results clearly demonstrate that SREBP-activated Dhcr7 promoter preferentially required the CCAAT1 element in HepG2 cells. However, GC3 site for Sp1 may contribute to the basal Dhcr7 promoter activity in response to sterol.
The purpose of this study was to determine how multiple motifs in
the proximal promoter region are involved in sterol-mediated regulation
of the Dhcr7 gene. Using combinations of deletion and site-specific
mutations in the Dhcr7 promoter, we have identified and characterized
cis-acting elements involved in the sterol-mediated regulation, which requires differential interaction of Sp1 (to GC3),
NF-Y (to CCAAT1), and SREBP-1 (to SRE1/E box). (Fig. 3, Fig. 8
and Fig. 10). Mapping of the Dhcr7 promoter with respect to
sterol-mediated gene expression was important for two reasons. First,
Dhcr7 is involved in the final reaction of cholesterol biosynthesis, so
control of gene expression by the end product (cholesterol) was
intriguing. Second, since mutations of Dhcr7 genes already were found
to be associated with SLOS, regulation of its gene expression should be
critical for normal development. The results presented in this paper
provided at least three interesting points with regard to Dhcr7 gene
expression. First, rat Dhcr7 gene expression can be regulated by
exogenous sterols including the end product, cholesterol (Fig. 1). In
particular, 25-hydroxycholesterol effects seem dominant since induction
of Dhcr7 promoter activity, mediated by sterol starvation condition,
was abolished by this sterol regardless of the presence of cholesterol
biosynthesis inhibitors (Fig. 5). Second, sterol-mediated Dhcr7 gene
regulation appears to require participation of specific GC boxes
(i.e. GC3 at 177,
172,
125, and
20), NF-Y (at
88 and
51),
and SREBP-1 or ADD1 (at
33). Deletion analysis of the Dhcr7 gene
promoter (
1053/+31), employing a nested series of Dhcr7-luciferase
constructs, demonstrated that the
179 upstream region of the gene is
necessary and sufficient for optimal efficient sterol-regulated
transcription. DNase I footprinting and electrophoretic mobility shift
assay showed that the SRE1/E box (
33/
22) involved in sterol
response of many sterol-related enzyme genes was protected specifically
by the overexpressed recombinant ADD1. Mutational analysis for the
functional relationship between the identified cis-elements
in this region indicate that one of the binding sites for Sp1 (GC box
at
125) and NF-Y (CCAAT box at
88) plays a cooperative role in the
sterol-mediated activation, in which the latter site also acts as a
co-regulator for SREBP-activated Dhcr7 promoter activity. We believe
that Dhcr7 is the first enzyme characterized with a sterol-regulatory
function in the post-lanosterol pathway. This may be important for
understanding the coordinated control of cholesterol biosynthesis as
well as the molecular mechanism of Smith-Lemli-Opitz syndrome-related
protein in mammals.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
7-double bond of sterol intermediates, which is the
terminal reaction, in the pathway of cholesterol biosynthesis from
lanosterol (1-3). Studies of this enzyme have recently drawn our
attention due to its implication in both cholesterol metabolism and
mammalian developmental biology (4-6). In particular, mutations of
Dhcr7 has been involved in genetic disease such as Smith-Lemi-Opitz
syndrome (SLOS) (7-9), which is an autosomal recessive disorder with
various developmental abnormalities. SLOS is characterized by elevated
7-dehydrocholesterol in serum (10-18). This connection between
cholesterol and the developmental program in mammals was established
based on the critical role of cholesterol in autoprocessing of sonic
hedgehog (shh) protein (5, 6, 19), a morphogen, which binds to, patched
protein in developing the central nervous system and limbs. For
example, the mouse mutated in shh showed SLOS-like phenotype (20,
21).
179 to +1), which controls transcriptional induction of the
gene in response to starvation of cellular sterols.
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]dCTP (3000 Ci/mmol), [
-32P]ATP (3000 Ci/mmol),
poly(dI-dC) ·poly(dI-dC), Amersham Pharmacia Biotech; DNA
sequencing reagents, PerkinElmer Life Sciences; restriction endonucleases, T4-DNA ligase, T4-polynucleotide kinase, and Klenow fragment of DNA polymerase I, New England Biolabs; RNasin ribonuclease inhibitor and avian myeloblastosis virus-reverse transcriptase, Promega; lipoprotein-deficient serum (LPDS), Sigma; Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), gentamycin, and L-glutamine, Life Technologies; sterols
including cholesterol and various oxysterols including 25-, 20-, 19-, 4-, 7
-, 7
-hydroxycholesterols, 6-keto, and 7-keto-sterols,
Steraloid. The sources of the following drugs or agents are also
indicated. AY-9944, Dr. D. Dvornik at Wyth-Ayerst, Princeton; and
LovastatinTM, Dr. Y-K. Sim at Choongwae Pharmaceutical Co., Korea.
70 °C. The signals that
appeared in the membranes were quantitatively analyzed with a BAS 2500 system (Fuji Photo Film Co.) and normalized to the quantity of
-actin mRNA expression.
1053 to +31 nucleotides,
followed by insertion into the SmaI site of the luciferase vector pGL3-Basic (Promega). Plasmid p7R1084 (
1053/+31) was digested with NheI and PvuII to remove the 5'-fragment
(NheI/PvuII) of the Dhcr7 insert, and religated
after treatment with T4 DNA polymerase to produce p7R537 (
506/+31).
In the same manner, p7R1084 was digested with PstI,
BstXI, and ApaI, and religated to produce p7R318
(
287/+31), p7R210 (
179/+31), and p7R148 (
117/+31), respectively. Plasmid p7R164 (
133/+31) and p7R72 (
41/+31) were generated by cloning PCR products obtained by using appropriate synthetic
oligonucleotides into a SmaI-digested pGL3-Basic vector. The
truncated chimeric plasmid p7R287-117 was prepared by inserting a
171-bp PstI/ApaI fragement of p7R1084 into a
SmaI-digested pGL3-Basic vector. All luciferase reporter
genes except p7R287-117 had the same 3' end in a SmaI site
of pGL3-Basic and varying 5' ends. All plasmids were verified by DNA sequencing.
46/
18); 5'-GTAGTCTGTGACCAGTAATCACCTGGGGG-3', E box/m
(
46/
18); 5'-GTAGTCTGTGACCTCACGTCACTACGGGG-3', SRE·E
box/m (
46/
18); 5'-GTAGTCTGTGACCAGTAATCACTACGGGG-3', ADD/m
(
46/
18); 5'-GTAGTCTGTTCCCAGTAATTCGTACGGGG-3',
NFY/m (
64/
33); 5'-GAAATCCACTTCGGAGATCTAGTCTGTGACCT-3',
GC1·2/m (
191/
156);
5'-GTCCCCAGGGGCGTGGGATGGTTGGGGCTGGCCCTG-3', CCAAT/m (
100/
69); 5'-GCTCACTGCCTTCAGATCTCACAGGGCGCGG-3', GC3/m (
135/
109); 5'-GCCGCCGACTGTATTGCCCGGTGGGCT-3',
GC4/m (
29/
3); 5'-GTCACCTGGGTTGAGTGCTTCAGGCAG-3', SRE/m1
(
46/
18); 5'-GTAGTCTGTGACCTCACGTTCGCTGGGGG-3', SRE/m2
(
46/
18); 5'-GTAGTCTGTGACCAGTAATTCGCTGGGGG-3'.
The PCR reaction products were digested with restriction enzymes
and inserted into the luciferase vector pGL3-Basic. The DNA sequence of
each mutant clone was confirmed by sequencing.
258/+41) were prepared from Dhcr7 gene and incubated with 0.2 or 2 µg of purified ADD1 protein in Buffer A (10 mM Tris
(pH 7.6), 100 mM KCl, 10 mM MgCl2,
1 mM EDTA, 1 mM dithiothreitol, and 4 µg of
poly(dI-dC)·poly(dI-dC)) at room temperature for 30 min in a total
volume of 20 µl. At the end of the reaction, 80 µl of a solution
containing 3 mM CaCl2 and 6 mM
MgCl2 was added the mixture. After digestion with DNase I, the DNA samples were extracted by a phenol/chloroform solution and
electrophoresed on a 6% sequencing gel with a same end-labeled sequencing ladder.
70 °C. For EMSA, annealed
oligonucleotide probes were 5'-end labeled using
[
-32P]ATP by T4-ploynucleotide kinase. Binding
reactions were carried out in Buffer A in the presence of 1 mg/ml
bovine serum albumin. Approximately 0.1 pmol of the labeled probe was
mixed with 2-6 µg of nuclear extract or 10-100 ng of recombinant
ADD1 in 20 µl, then incubated for 30 min at room temperature. EMSA
was performed on a 5% polyacrylamide gel with 0.5 × TBE buffer
(40 mM Tris borate, 1 mM EDTA) and processed
for autoradiography. For binding competition assays, 100-fold molar
excess of unlabeled oligonucleotides were added before the addition of
labeled probe. The DNA sequence of oligonucleotides used were as
follows: ADD (ADD1-binding site of Dhcr7 promoter),
5'-GTAGTCTGTGACCTCACGTCACCTGGGGG-3'; GC3 (Sp1-binding site of
Dhcr7 promoter), 5'-CGCCGACTGGCGGGCCCGGTGG-3'; CCAAT1 (NF-Y-binding
site of Dhcr7 promoter), 5'-CTGCCTTCACCAATCACAGGGC-3'; GC-box
(Sp1-binding site), 5'-ATTCGATCGGGGCGGGGCGAGC-3'; CCAAT box (NF-Y
binding site), 5'-GTGATCAGCCAATCAGAGCGAG-3'; ABS (ADD1-binding site: E
box), 5'-GATCCTGATCACGTGATCGAGGAG-3'; and SRE-1,
5'-GATCCTGATCACCCCACTGAGGAG-3'.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (68K):
[in a new window]
Fig. 1.
Effects of LPDS medium, sterol and
cholesterol-lowering drugs on expression of Dhcr7 mRNA.
A, after H4IIE and CHO-K1 were incubated for 24 h in
either FBS or LPDS medium at 70% confluence, total RNA was isolated
from the cells. Twenty µg of the total RNAs were electrophoresed on a
1% agarose gel and transferred to a Hybond N+ membrane.
The filter was hybridized with 32P-labeled rat Dhcr7
cDNA probe and exposed to film. The same filter was subsequently
hybridized with -actin probe. B and C, H4IIE
cells were cultured in normal medium containing 0, 0.01, 0.1, and 1 µM AY9944 (lanes 1-4
(B), or LPDS medium containing 0, 0.01, 0.1, 1, 10 µM Lovastatin (lanes 1-5
(C)). After 24 h incubation, total RNA was prepared
from the cells and 20 µg of RNA subjected to Northern blot analysis.
D, H4IIE cells were cultured in LPDS medium containing 0, 0.01, 0.05, 0.1, and 0.5 µg/ml 25-hydoxycholesterol (lanes
1-5 (D)). After 24 h incubation, total RNA
was prepared from the cells and 20 µg of RNA subjected to Northern
blot analysis. 25-OH, 25-hydroxycholesterol.
179 to +1) is 67% G + C and contains several well
known transcription factor binding sites (Fig. 2). These are four GC boxes binding to Sp1 (
177/
172 (GC1),
172/
167 (GC2),
125/
121 (GC3), and
20/
15(GC4)), two CCAAT boxes binding to NF-Y (
88/
81 (CCAAT1) and
51/
45 (inverted, CCAAT2)) and an SRE1/E box binding to
SREBP-1 or ADD1 (
33/
22). These regulatory sites are regarded as
typical motifs seen in several genes involved in cholesterol homeostasis (26-34). There was no TATA box within the promoter region
of the Dhcr7, implying the presence of multiple transcription start
sites as previously demonstrated.2 The transcription start
site by the longest 5'-rapid amplification of cDNA ends product is
located at an adenine (A) residue, which is 307 bp away from the ATG
codon in Dhcr7 cDNA2 (Fig. 2). Therefore, Dhcr7 gene
transcription appears to be driven by a TATA-less GC-rich promoter.
This 5'-flanking region of the Dhcr7 promoter (
1053 to +1) also
contains other well characterized regulatory elements that may control
expression of this gene. These include two AP-1 (
454/
449 and
130/
125), four AP-4 (
510/
505,
290/
284,
167/
162, and
103/
98), NF-1 (
422/
417), NFAT (
555/
550), and SRY
(
521/
516) binding sites. There are many IK2 and MZF-1-binding sites
in the Dhcr7 promoter and part of intron 1. With regard to
sterol-mediated regulation, we have focused on the proximal region
(
179/+1) for further analysis on Dhcr7 gene transcription.
View larger version (69K):
[in a new window]
Fig. 2.
Nucleotide sequence of the 5'-flanking region
of rat Dhcr7 gene. The sequence shown contains 1053 nucleotides 5'
to the transcription start site of the longest mRNA transcript. The
adenine at the transcription start site is designated +1. Putative
transcriptional regulatory elements are underlined and
identified below the sequences in bold letters.
1053 to
+31. Each deletion construct was prepared by inserting DNA fragments of
various lengths into the luciferase gene and then analyzed for promoter
activity using a transient assay system, as described under
"Experimental Procedures." These deletion constructs were
transfected into HepG2 cells and their luciferase activities measured
following treatment with sterols (Fig.
3). To normalize activity in different
transfected cells, we co-transfected the cells with pRL-SV40, a non
sterol-regulated Renilla luciferase expression vector.
Results were expressed as "-fold" activation by taking the ratio of
the luciferase activities after sterol starvation (
sterol) or sterol
supplemented (+sterol) conditions. For the analysis of the regulation
of the Dhcr7 promoter, HepG2 cells were chosen due to their relatively
high transfection efficiency (>30-fold) as compared with that of H4IIE
cells (data not shown). The promoter activity of the longest fragment,
beginning at
1053 (p7R1084), was set at 100% for the results
obtained from HepG2 cells in 5% LPDS (plus 10 µM
Lovastatin; sterol starvation condition). The basal promoter activity
was set at the luciferase activity of p7R72 (
41/+31). As shown in
Fig. 3, the promoter activity of the parent construct (p7R1084) was
decreased more than 11-fold when sterol (1.5 µg/ml
25-hydroxycholesterol) was added into the LPDS media, confirming the
presence of sterol-mediated regulatory elements such as the SRE1/E box
located at
33/
22 in the 5'-flanking region (Fig. 2). Deletion of
regions spanning nucleotides
1053 and
133 (p7R537, p7R318, p7R210,
and p7R164) caused no significant change in either promoter activity or
sterol-mediated activation of Dhcr7 promoter activity. However,
deletion of nucleotides between
133 and
117 caused almost a
3.5-fold reduction in both the promoter activity relative to
the
133 region and the sterol-mediated activation. That is, there was
a change in the magnitude of sterol-mediated activation between these
two constructs (
133/+31 (13.6-fold) versus
117/+31
(4.0-fold)). This result suggests the presence of positive
cis-acting sequences in this region (
133 and
117), which
seems sensitive to the absence of sterol. This is further confirmed by
the fact that the deletion constructs, p7R148 (
117/+31) and p7R72
(
41/+31), almost abolished a sterol-mediated activation (~4.0 to
~2.9-fold). Therefore, it appears that the two tandem repeat GC boxes at
177 (GC1) and
172 (GC2) are less important than
other proximal GC boxes (e.g. GC3) for Dhcr7 promoter
activity in response to sterols. Addition of the fragment containing
sterol-regulated regions which enhanced activity (
287/
117) of the
reporter gene itself (pGL3-Basic vector; e.g. p7R287-117),
exhibited much lower luciferase activity in the absence of sterol than
that of basal promoter construct, suggesting the absence of promoter
activity in this sequence. A similar pattern of expression was also
observed for these constructs when they were transfected into either
CHO-K1 cells or H4IIE cells (Fig. 4).
Therefore, we have focused on nucleotides spanning
287 to +31 (p7R318
showed the highest activity on sterol depletion conditions) in the
5'-flanking region of the rat Dhcr7 gene for further analysis of sterol
response.
View larger version (31K):
[in a new window]
Fig. 3.
Relative promoter activity and response to
sterols of Dhcr7 promoter luciferase-chimeric genes. Luciferase
activities were measured in HepG2 cells that had been transfected with
both a Dhcr7 promoter-luciferase construct and a pRL-SV40 plasmid
(Promega) as an internal control in the presence or absence of sterols.
Relative luciferase activities were determined as a ratio of luciferase
activity of each sample to the activity of Renilla
luciferase and were normalized to 100 for p7R1084 in the absence of
sterols. For the starvation of sterols, cells were incubated in 5%
LPDS containing media in the presence of 10 µM
Lovastatin. In the presence of sterols, cells were incubated in the
same LPDS media in the presence of 1.5 µg/ml 25-hydroxycholesterol.
Values shown here are the mean ± S.D. (n = 4).
View larger version (42K):
[in a new window]
Fig. 4.
Comparison of promoter activities of fusion
genes containing varying lengths of the Dhcr7 promoter in HepG2, H4IIE,
and CHO-K1. Cells were co-transfected with one of the chimeric
genes p7R1084, p7R537, p7R318, p7R210, p7R164, p7R148, p7R72, or
p7R287-117 and with a pRL-SV40 plasmid for an internal control. Cells
were maintained in LPDS-containing media in the presence of 10 µM Lovastatin. Relative luciferase activities were
determined as a ratio of luciferase activity of each sample to the
activity of Renilla luciferase and were normalized to 100 for p7R1084 in all cells. The relative activity of p7R1084 in HepG2 was
1.4 and 3.8 times higher than in H4IIE and CHO-K1 cells. Values shown
here are the mean from three independent experiments.
287/+31) in the presence of different oxysterols. As shown in Fig.
5, 25-hydroxycholesterol was found to be
the strongest regulator among the seven oxysterols examined. However, the addition of Dhcr7 inhibitor (AY-9944, 2 µM) or
HMG-CoA reductase inhibitor (lovastatin, 20 µM) to the
LPDS media (sterol depletion conditions) resulted in increases of 150 and 180% in HepG2 cells that had been transfected with p7R318. The
concentration of Lovastatin or AY-9944 was empirically determined prior
to this experiment. These results are consistent with those of
endogenous mRNA expression under similar conditions (Fig. 1,
B and C). As expected, addition of
25-hydroxycholesterol to LPDS medium abolished the AY-9944- or
Lovastatin-induced activation of Dhcr7 promoter activity (Fig. 5),
suggesting a dominant suppressive role for 25-hydroxycholesterol. In
FBS medium (a sterol-supplemented condition), Lovastatin (HMG-CoA reductase inhibitor) produced a 3-fold increase of Dhcr7
promoter activity; AY-9944 (Dhcr7 inhibitor) only resulted in 1.3-fold induction, implying a different mode of action for these inhibitors in
FBS media.
View larger version (32K):
[in a new window]
Fig. 5.
Expression of luciferase reporter gene
containing rat Dhcr7 promoter in HepG2 cells maintained in different
drugs or sterols, in either LPDS or FBS media. HepG2 cells were
transfected with p7R318 ( 287/+31) and exposed to medium containing
5% (v/v) LPDS or 5% FBS media supplemented with 1.5 µg/ml
25-hydroxycholesterol (25-OH), 20-hydroxycholesterol
(20-OH), 19-hydroxycholesterol (19-OH),
4-hydroxycholesterol (4-OH), 7
-hydroxycholesterol
(7
-OH), 7
-hydroxycholesterol (7
-OH),
6-ketosterol (6-keto), 7-ketosterol (7-keto); 10 µg/ml cholesterol (Chol), and the cholesterol biosynthesis
inhibitor 2 µM AY-9944 (AY) or 20 µM Lovastatin (Lova). After incubation for
40 h with the appropriate media, the cells were harvested assayed
for luciferase activity. Data are the average of two separate
determinations.
258/+41 and a synthetic 29-mer oligonucleotide
binding to ADD1. As shown in Fig.
6A, a recombinant ADD1 binds
specifically to the proximal promoter specifically in a dose-response
fashion, and its binding to the probe was abolished by the addition of 100-fold molar excess of a double-stranded 29-mer oligonucleotide competitor. As shown in Fig. 6B, the sequence elements such
as SRE1/E box involved in sterol response of Dhcr7 was protected by
overexpressed recombinant ADD1. A footprint covering nucleotides
40
to
22 was clearly visible; this protected region includes the
consensus SRE1/E box (
33/
22). The binding of overexpressed ADD1 to
the Dhcr7 promoter was also observed by EMSA (Fig. 6C). The
annealed double-stranded oligonucleotides probe ADD (
46 to
18),
containing SRE1/E box, binds efficiently to ADD1 in EMSA. Its specific
binding intensity was reduced in the presence of a 100-fold
molar excess of specific competitors such as ABS (contained ADD1-binding site: E box) and SRE-1 consensus sequence (Fig.
6C). However, binding competition was not observed for any
of these mutant oligonucleotide competitors (lanes
4-5 in Fig. 6C). These results suggest that the
required sequences for binding to the overexpressed ADD1 are located
within the nucleotides between
40 and
22, which are overlapped with
E box. To examine any binding specificity for Sp1 and NF-Y to the
proximal region of Dhcr7 promoter, EMSA was performed using the
appropriate probes covering this region in the presence or absence of
competitor. Specifically, GC3 at
125 binds to Sp1 and CCAAT1 at
88
binds to NF-Y (Fig. 7, A and
B). These results provide direct evidence that sequences proximal to nucleotide
133 serve as binding sites for both Sp1 and
NF-Y.
View larger version (78K):
[in a new window]
Fig. 6.
SREBP-1/ADD1 binds to sequences in the
proximal rat Dhcr7 promoter. A, a probe corresponding
to nucleotides 137 to +41 and containing the SRE-1 was generated by
PCR from the Dhcr7 promoter. This probe was end-labeled with
[
-32P]dCTP and incubated with ADD1 (lanes 2 and 3) and competitor double strand-ADD (lane
4). B, the end labeled probe (
258 to +41) was
incubated in the absence or presence of recombinant ADD1. DNase I
digestion was performed and the resulting products were separated by
denaturing polyacrylamide gel electrophoresis with the same end-labeled
sequencing ladder. The presence of a DNase I protected region and its
corresponding nucleotide sequence are indicated. The proteins added are
0.2 µg (lane 1) and 2 µg (lane
2) of ADD1, and 2 µg of bovine serum albumin
(lane 3), respectively. C, EMSA of
double strand-ADD by binding to ADD1. The double-stranded oligomer
(ds-ADD) containing the SRE-1 sequence was used as the
probe. The labeled probe was added into the reaction mixture that
contained the recombinant ADD1 and 100-fold molar excess amount of
competitor oligonucleotides as described under "Experimental
Procedures." Lane 1, unbound ds-ADD probe;
lanes 2 and 3 probe incubated with 20 and 100 ng of recombinant ADD1; lanes 4-7, show
competition assays. Separation was done by electrophoresis on a 5%
native polyacrylamide gel.
View larger version (73K):
[in a new window]
Fig. 7.
Sp-1 and NF-Y binding to the GC3 and CCAAT1
sequences in the rat Dhcr7 promoter. EMSA was performed with
nuclear extract of H4IIE cells as described under "Experimental
Procedures." The 32P-labeled DNA probes (nucleotides
133 to
112: Panel A,
95 to
74: Panel B)
were generated by using polynucleotide kinase. Lanes 1 and
5, DNA probe only; lane 2, DNA probe incubated
with cell extract; lane 3, same as in lane 2, but
the binding reaction contained a 100-fold excess of the consensus GC
box (Panel A) or CCAAT box (Panel B) as
competitor; lane 4, as in lane 3, except
containing mutant competitor at the Sp-1-binding site (Panel
A) or NF-Y-binding site (Panel B).
287 upstream region
of the Dhcr7 promoter is both necessary and sufficient for optimal
sterol-regulated transcription. To further investigate functional
relationships between the identified cis-elements in the
Dhcr7 promoter, which are shown to be involved in the sterol-mediated
regulation, we introduced a series of multiple point mutations into
this region and fused the resulting mutant promoters to a luciferase
reporter gene. Each construct was then transiently transfected into
HepG2 cells and assayed for sterol-regulated transcription by
maintaining the transfected cells either under induced (sterol
starvation) or suppressed (supplementation of 25-hydroxycholesterol)
conditions. Constructs containing mutations within the region
287 to
+1, relative to the transcription start site are shown (Fig.
8), and the ratio of reporter gene
activity obtained from either induced or suppressed conditions is
reported as -fold activation (
sterol/+sterol). Mutations
of the two distal Sp1-binding sites (
GC1/GC2; M1), second
NF-Y-binding site (
CCAAT2; M7), and SREBP/ADD1-binding site
(
SRE1/E-box; M9-M11) caused no change in sterol-mediated response
(Fig. 8). However, mutation of either the third Sp1-binding site
(
GC3; M2, M3) or the first NF-Y-binding site (
CCAAT1; M5, M6)
caused a reduction of sterol regulatory response. Mutations of the
proximal Sp1-binding site (
GC4; M4, M12) and the whole region of
SRE1/E box or the SRE1 part of SREBP/ADD1-binding sites (
SRE1/E box;
M8,
SRE; M13, M14) caused moderate change in sterol regulatory
response. Taken together, these results suggest that GC3 and CCAAT1 are
essential to the sterol-mediated regulation of the Dhcr7 promoter. The
data shown in Fig. 8 confirmed that the sequences located between
nucleotides
33 and
25 are functional SRE-1 of the rat Dhcr7
promoter and behave as the direct repeat element 5'-PyCAPy-3',
like other sterol-response genes (35, 36).
View larger version (43K):
[in a new window]
Fig. 8.
Mutational analysis of Dhcr7 promoter
region. Transversal replacement mutations were introduced into the
Dhcr7-luciferase chimeric construct, p7R318 ( 287/+31). The Dhcr7 gene
promoter-luciferase constructs are shown together with potential
regulatory elements marked as boxes. HepG2 cells were
transfected with one of the mutant reporter constructs and incubated in
5% LPDS in the presence of 10 µM Lovastatin (an induced
condition) or 1.5 µg/ml 25-hydroxycholesterol (a suppressed
condition) for 48 h. The data are expressed as "fold"
activation by dividing the activity under sterol starvation
(
sterol) by the activity under sterol supplement
(+sterol).
View larger version (43K):
[in a new window]
Fig. 9.
Differential SREBP-activated expression of
rat Dhcr7 promoter. A, the p7R318 transfected HepG2
cells (50-70% confluence) were co-transfected with different amounts
of pSREBP1 plasmid for 24 h and incubated in RPMI 1640 and 5%
LPDS in the presence of 1.5 µg/ml 25-hydroxycholesterol to suppress
endogenous SREBPs, and analyzed by a standard transient transfection
assay for luciferase expression from a Dhcr7 promoter construct,
p7R318. B, HepG2 cells were co-transfected with 50 ng of
pSREBP1 and the indicated Dhcr7 promoter deletion constructs along with
the reference plasmid pRL-SV40. After transfection, the cells were
incubated in RPMI 1640 with 5% LPDS supplemented with 1.5 µg/ml
25-hydroxycholesterol. Values are means of three independent
experiments.
View larger version (41K):
[in a new window]
Fig. 10.
Role of multiple regulatory elements of
Dhcr7 promoter in SREBP-activated expression. Each reporter
construct was co-transfected with pSREBP1 into HepG2 cell. After
transfection, the cells were incubated in RPMI 1640 with 5% LPDS
supplemented with 1.5 µg/ml 25-hydroxycholesterol. Indicated values
are fold changes of the values from SREBP-1 expression experiment
relative to control values. Data shown are mean ± S.D.
(n = 4).
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
125/
120) and a CCAAT box (CCAAT1 at
88/
81) in addition to the SRE1/E box sequence (
33/
22). In
addition, the most critical nucleotide sequence(s) in the
SRE/E box was found to be Segment II of the SRE/E
box ("5'-TCAC"-3', Table
I) because mutation of this portion
(i.e. M13 in Fig. 8) caused more change in sterol responsiveness of SRE/E box as compared with those in other
segments (Segments I or III) of SRE/E box sequences, for
example, M9, M10, and M11.
SRE1/E box sequences of Dhcr7 promoter
Sequence analysis also revealed that the rat Dhcr7 promoter region contains high GC content and lacks a canonical TATA box, suggesting that it has overall similarity to promoters of HMG-CoA reductase and human squalene synthase in the cholesterol biosynthesis pathway and a number of housekeeping genes (29, 33, 39). Third, the fact that activation of Dhcr7 by addition of AY-9944 or Lovastatin led to a notion that the endogenous sterol can down-regulate the sterol-sensitive Dhcr7 gene, as evidenced by data in Fig. 1. Taken together, the maximal activation of Dhcr7 promoter by sterol starvation requires multiple cis-acting elements that are known to utilize the general transcription factors, NF-Y, Sp1, and ADD1, the rat homolog of SREBP-1, which may have some roles in recruiting SREBP-1, as well as activating it in these promoters. Although both NF-Y and Sp1 appear to work in a concerted manner in sterol-mediated regulation, the former participates in SREBP-1-mediated activation, while the latter acts in general transcription activation. A similar case may be the promoters of fatty acid synthase and the LDL receptor gene which require the SREBP-1 and generic co-regulator Sp1 for synergistic activation (34, 40). Recently, the synergistic activation by SREBP-1 and Sp1 has also been reviewed on an artificially assembled chromatin template in vitro and Sp1 has been shown to interact with NF-Ya in vitro in the absence of DNA (41, 42). Hence, it is believed that an interaction between NF-Y and Sp1 plays a crucial role in the sterol regulation of rat Dhcr7 promoter. Direct evidence should come from studies of promoter-factor interaction.
In conclusion, SLOS-related Dhcr7 is the first enzyme in the
post-lanosterol pathway displaying a typical sterol-mediated gene
regulation, thereby providing concerted, coordinated control of
cholesterol biosynthesis between enzymes in the earlier pathway (HMG-CoA reductase and squalene synthase) and those in the distal pathway.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Drs. Bruce M. Spiegelman, Jae B. Kim, and Timothy F. Osborne for their kind provision of the expression plasmids.
![]() |
FOOTNOTES |
---|
* This work was supported in part by KOSEF, KDR Co. and Molecular Medicine project Grant 98-J03-02-04-A-03 (to Y. K. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Yonsei University,
Dept. of Biochemistry, 134 Shinchon-dong, Sudaemoon-ku, Seoul, 120-749, Korea. Tel.: 82-2-2123-4242; Fax: 82-2-393-6589 or 362-9897; E-mail:
paikyk@yonsei.ac.kr.
Published, JBC Papers in Press, March 13, 2001, DOI 10.1074/jbc.M101661200
2 J. N. Lee, S.-H. Bae, and Y.-K. Paik, submitted for publication.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: Dhcr7, 7-dehydrocholesterol reductase; ADD1, adipocyte determination and differentiation-dependent factor 1; LPDS, lipoprotein-deficient serum; FBS, fetal bovine serum; SRE, sterol regulatory element; SREBP, SRE-binding protein; NF-Y, nuclear factor Y; EMSA, electrophoretic mobility shift assay; shh, sonic hedgehog; SLOS, Smith-Lemi-Opitz syndrome; PCR, polymerase chain reaction; bp, base pair(s); HMG, hydroxymethyl glutaryl.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Gibbon, G. F.,
Goad, L. J.,
Goodwin, T. W.,
and Nes, W. R.
(1971)
J. Biol. Chem.
246,
3967-3976 |
2. | Lee, J. N., and Paik, Y.-K. (1997) J. Biochem. Mol. Biol. 30, 370-377 |
3. | Bae, S.-H., and Paik, Y.-K. (1997) Biochem. J. 326, 609-616[Medline] [Order article via Infotrieve] |
4. |
Bae, S.-H.,
Lee, J. N.,
Fitzky, B. U.,
Seong, J.,
and Paik, Y.-K.
(1999)
J. Biol. Chem.
274,
14624-14631 |
5. | Porter, J. A., Young, K. E., and Beachy, P. A. (1996) Science 11, 255-259[CrossRef] |
6. | Cooper, M. K., Porter, J. A., Young, K. E., and Beachy, P. A. (1998) Science 5, 1603-1607[CrossRef] |
7. |
Fitzky, B. U.,
Witsch-Baumgartner, M.,
Erdel, M.,
Lee, J. N.,
Paik, Y.-K.,
Glossmann, H.,
Utermann, G.,
and Moebius, F. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8181-8186 |
8. | Waterham, H. R., Wijburg, F. A., Hennekam, R. C., Vreken, P., Poll-The, B. T., Dorland, L., Duran, M., Jira, P. E., Smeitink, J. A., Wevers, R. A., and Wanders, R. J. (1998) Am. J. Hum. Genet. 63, 329-338[CrossRef][Medline] [Order article via Infotrieve] |
9. | Wassif, C. A., Maslen, C., Kachilele-Linjewile, S., Lin, D., Linck, L. M., Conner, W. E., Steiner, R. D., and Porter, F. D. (1998) Am. J. Hum. Genet. 63, 55-62[CrossRef][Medline] [Order article via Infotrieve] |
10. | Smith, D. W., Lemli, L., and Opitz, J. M. (1964) J. Pediatr. 64, 210-217[Medline] [Order article via Infotrieve] |
11. | Tint, G. S., Irons, M., Elias, E. R., Batta, A. K., Frieden, R., Chen, T. S., and Salen, G. (1994) N. Engl. J. Med. 13, 107-113 |
12. | Irons, M., Elias, E. R., Tint, G. S., Salen, G., Frieden, R., Buie, T. M., and Ampola, M. (1994) Am. J. Med. Genet. 1, 347-352 |
13. | Tint, G. S., Seller, M., Hughes-Benzie, R., Batta, A. K., Shefer, S., Genest, D., Irons, M., Elias, E., and Salen, G. (1995) J. Lipid Res. 36, 89-95[Abstract] |
14. | Alley, T. L., Gray, B. A., Lee, S. H., Scherer, S. W., Tsui, L. C., Tint, G. S., Williams, C. A., Zori, R., and Wallace, M. R. (1995) Am. J. Hum. Genet. 56, 1411-1416[Medline] [Order article via Infotrieve] |
15. | Honda, A., Batta, A. K., Salen, G., Tint, G. S., Chen, T. S., and Shefer, S. (1997) Am. J. Med. Genet. 31, 288-293[CrossRef] |
16. | Kelley, R. L., Roessler, E., Hennekam, R. C., Feldman, G. L., Kosaki, K., Jones, M. C., Palumbos, J. C., and Muenke, M. (1996) Am. J. Med. Genet 66, 478-484[CrossRef][Medline] [Order article via Infotrieve] |
17. | Shefer, S., Salen, G., Honda, A., Batta, A., Hauser, S., Tint, G. S., Honda, M., Chen, T., Holick, M. F., and Nguyen, L. B. (1997) Metabolism 46, 844-850[CrossRef][Medline] [Order article via Infotrieve] |
18. | Anderson, A. J., Stephan, M. J., Walker, W. O., and Kelley, R. I. (1998) Am. J. Med. Genet. 6, 413-418[CrossRef] |
19. | Porter, J. A., Ekker, S. C., Park, W. J., von Kessler, D. P., Young, K. E., Chen, C. H., Ma, Y., Woods, A. S., Cotter, R. J., Koonin, E. V., and Beachy, P. A. (1996) Cell 12, 21-34 |
20. | Chiang, C., Litingtung, Y., Lee, E., Young, K. E., Corden, J. L., Westphal, H., and Beachy, P. A. (1996) Nature 383, 407-413[CrossRef][Medline] [Order article via Infotrieve] |
21. | Lanoue, L., Dehart, D. B., Hinsdal, M. E., Maeda, N., Tint, G. S., and Sulik, K. K. (1997) Am. J. Med. Genet. 73, 24-31[CrossRef][Medline] [Order article via Infotrieve] |
22. |
Moebius, F. F.,
Fitzky, B. U.,
Lee, J. N.,
Paik, Y.-K.,
and Glossmann, H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
1899-1902 |
23. |
Lecain, E.,
Chenivesse, X.,
Spagnoli, R.,
and Pompon, D.
(1996)
J. Biol. Chem.
271,
10866-10873 |
24. | Kim, J. B., Spotts, G. D., Halvorsen, Y. D., Shih, H. M., Ellenberger, T., Towle, H. C., and Spiegelman, B. M. (1995) Mol. Cell. Biol. 15, 2582-2588[Abstract] |
25. | Dignam, J. D., Levovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract] |
26. |
Bennett, M. K.,
Ngo, T. T.,
Athanikar, J. N.,
Rosenfeld, J. M.,
and Osborne, T. F.
(1999)
J. Biol. Chem.
274,
13025-13032 |
27. |
Dooley, K. A.,
Millinder, S.,
and Osborne, T. F.
(1998)
J. Biol. Chem.
273,
1349-1356 |
28. |
Ericsson, J.,
Jackson, S. M.,
and Edwards, P. A.
(1996)
J. Biol. Chem.
271,
24359-24364 |
29. |
Guan, G.,
Jiang, G.,
Koch, R. L.,
and Shechter, I.
(1995)
J. Biol. Chem.
270,
21958-21965 |
30. |
Jackson, S. M.,
Ericsson, J.,
Mantovani, R.,
and Edwards, P. A.
(1998)
J. Lipid Res.
39,
767-776 |
31. | Natarajan, R., Ghosh, S., and Grogan, W. M. (1998) Biochem. Biophys. Res. Commun. 243, 349-355[CrossRef][Medline] [Order article via Infotrieve] |
32. |
Sanchez, H. B.,
Yieh, L.,
and Osborne, T. F.
(1995)
J. Biol. Chem.
270,
1161-1169 |
33. |
Spear, D. H.,
Kutsunai, S. Y.,
Correll, C. C.,
and Edwards, P. A.
(1992)
J. Biol. Chem.
267,
14462-14469 |
34. |
Xiong, S.,
Chirala, S. S.,
and Wakil, S. J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
3948-3953 |
35. |
Magana, M. M.,
and Osborne, T. F.
(1996)
J. Biol. Chem.
271,
32689-32694 |
36. |
Athanikar, J. N.,
and Osborne, T. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4935-4940 |
37. |
Wang, X.,
Briggs, M. R.,
Hua, X.,
Yokoyama, C.,
Goldstein, J. L.,
and Brown, M. S.
(1993)
J. Biol. Chem.
268,
14497-14504 |
38. |
Yieh, L.,
Sanchez, H. B.,
and Osborne, T. F.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
6102-6106 |
39. | Dynan, W. S. (1986) Trends Genet. 8, 196-197 |
40. |
Bennett, M. K.,
and Osborne, T. F.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
6340-6344 |
41. |
Naar, A. M.,
Beaurang, P. A.,
Robinson, K. M.,
Oliner, J. D.,
Avizonis, D.,
Scheek, S.,
Zwicker, J.,
Kadonaga, J. T.,
and Tjian, R.
(1998)
Genes Dev.
12,
3020-3031 |
42. | Roder, K., Wolf, S. S., Larkin, K. J., and Schweizer, M. (1999) Gene (Amst.) 234, 61-69[CrossRef][Medline] [Order article via Infotrieve] |